Lord, Abbett & Co
RYTM icon

Lord, Abbett & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

Lord, Abbett & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-348,953
Closed -$30.3M – 624
2026
Q1 		$30.3M Sell
348,953
-270,589
-44% -$26.3M 0.1% 220
2025
Q4 		$66.3M Buy
619,542
+43,558
+8% +$4.62M 0.2% 132
2025
Q3 		$58.2M Buy
575,984
+371,709
+182% +$34.5M 0.17% 148
2025
Q2 		$12.9M Buy
204,275
+68,915
+51% +$4.22M 0.04% 348
2025
Q1 		$7.17M Sell
135,360
-25,291
-16% -$1.4M 0.03% 419
2024
Q4 		$8.99M Buy
160,651
+58,005
+57% +$3.2M 0.03% 397
2024
Q3 		$5.38M Buy
102,646
+55
+0.1% +$2.63K 0.02% 473
2024
Q2 		$4.21M Sell
102,591
-178,566
-64% -$7.13M 0.01% 475
2024
Q1 		$12.2M Sell
281,157
-2,361
-0.8% -$103K 0.04% 373
2023
Q4 		$13M Buy
+283,518
New +$8.94M 0.05% 370

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lord, Abbett & Co's RYTM Position: Q2 2026 in Review

Lord, Abbett & Co sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 348,953 shares — an estimated $30.3M sold.

Lord, Abbett & Co first reported a position in RYTM in Q4 2023 and held it in 10 quarters. The position peaked at $66.3M in Q4 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Lord, Abbett & Co reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 348,953 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $30.3M.
  • Lord, Abbett & Co first reported a position in Rhythm Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Lord, Abbett & Co's Rhythm Pharmaceuticals position peaked at $66.3M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.